Skip to main content
$14.88 -0.29 (-1.91%)
Market Cap
$764.60M
Shares
50.40M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$15.17 Open$15.06 Day$15.04–15.49 52W$6.69–16.89 Avg vol 30d713K Short int2.5M · 5.0% float · 3.7d Short vol40% Last earningsAug 6, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 5

Up next

Next earnings call
Aug 6, 2026 Scheduled · in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 18.2 · elevated Equity put/call 0.71
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +38%
      above
      Price vs 50-day avg −1%
      below
      RSI (14) 45
      neutral
      MACD trend Negative
      52-week position 83%
      mid-range
      Momentum
      relative strength
      Strong
      1-month return −7%
      trailing
      6-month return +61%
      trailing
      YTD return +58%
      this year
      Relative strength +53%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $15 › 200d $11 — 50d above 200d
      Institutional flow Distributing
      27 of 165 funds reported for Jun 30 · net -357.9K sh shares · +3 new
      Insider flow Distributing
      Net -$3.6M over 90 days · 100% sells
      Short interest Rising
      5.00% of float · ▲ +15.7% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      165 holders — mid 3-yr range
      Squeeze score 64
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +12%
      Y/Y
      Gross margin 47%
      expanding
      EPS growth +156%
      Y/Y
      Free cash flow $-25.0M
      Valuation P/E 10.6
      below peers
      Buyback $37.1M
      remaining
      Balance sheet $249.2M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 65%
      annualized · 1-yr
      Max drawdown −32%
      past year
      ATR 5.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed May 4, 2026
      Full-year revenue · full-year Initiated $192M – $196M
      prior FY $176.18M midpoint +10.1% Y/Y
      Guided vs delivered · last 2 settled
      Total revenue from continuing operations full-year 2025
      guided $170M – $174M
      $176.18M Beat +2.4%
      Revenue full year
      guided $225M – $235M
      $228.39M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +38% Bullish
      Price vs 50-day avg
      −1% Neutral
      RSI (14)
      45 Neutral
      MACD trend
      Negative Bearish
      52-week position
      83% Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $15 › 200d $11 — 50d above 200d
      Institutional flow Distributing
      27 of 165 funds reported for Jun 30 · net -357.9K sh shares · +3 new
      Insider flow Distributing
      Net -$3.6M over 90 days · 100% sells
      Short interest Rising
      5.00% of float · ▲ +15.7% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      165 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $7 Now $15 · 83% 52-wk high $17
      vs 200-day avg +38% vs 50-day avg -1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Global clinical trials supported 766 Q1 2026
      Year-over-year improvement in adjusted EBITDA from continuing operations non-GAAP $2.2M Q1 2026
      Americas clinical trials supported 571 As of December 31, 2025
      APAC clinical trials supported 51 As of December 31, 2025
      Commercially approved therapies supported 20 Year ended December 31, 2025
      EMEA clinical trials supported 138 As of December 31, 2025
      Phase 1 clinical trials supported 313 As of December 31, 2025
      Phase 2 clinical trials supported 361 As of December 31, 2025
      Phase 3 clinical trials supported 86 As of December 31, 2025

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Integrated Freight & Logistics — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CYRX
      Cryoport, Inc.
      this stock
      $764.60M +58.0% -28.9% 10.6 5.0%
      UPS
      United Parcel Service Inc
      $89.70B +7.9% +8.2% 17.1 2.9%
      FDX
      Fedex Corp
      $73.96B +35.4% +8.5% 16.9 2.5%
      JBHT
      Hunt J B Transport Services Inc
      $26.07B +43.1% +0.4% 39.4 2.2%
      FDXF
      FedEx Freight Holding Company, Inc.
      $22.48B 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      168
      % held
      93.2%
      Reported
      27 of 165
      Top holder
      CADIAN CAPITAL MANAGEMENT…
      Held Float
      View
      Held by Funds
      Fund positions
      170
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      2.5M
      Days to cover
      3.7d
      Change
      +342.3K sh
      View
      Short Volume
      Short vol %
      40%
      As of
      Jul 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      300
      Value
      $4.4K
      As of
      Jun 16, 2026
      View
      Off-Exchange
      Off-exchange %
      50.6%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$3.6M
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Josh Gottheimer
      Amount
      $1.0K–$15.0K
      Traded
      Sep 15, 2023
      View
      Financials
      Financials
      Revenue (FY)
      $176.2M
      Net income (FY)
      $78.3M
      EPS diluted
      $1.40
      View
      Buybacks
      Authorized
      $100.0M
      Remaining
      $37.1M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 9, 2026
      This year
      6
      View
      Proposed Sales
      Value
      $486.2K
      Shares
      33.6K
      Filed
      Jun 11, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Aug 6, 2026
      Last call
      Jun 5, 2026
      View
      Investor Relations
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      CYRX -6.6% -6.8% +60.9% -3.4% +58.0%
      SPY -1.0% 0.0% +7.4% -0.8% +8.6%
      vs SPY -5.6% -6.8% +53.4% -2.6% +49.4%

      Capital returns

      Buyback program · as of Mar 31, 2024
      Authorized
      $100.00M
      Spent (derived)
      $62.90M
      Remaining
      $37.10M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1124524 CUSIP 229050307 13F (30d) 27 filings 27 filers Visit website Investor relations